Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial
- Type de publi. : Article dans une revue
- Date de publi. : 01/07/2023
-
Auteurs :
Bruce Stamblera John CammMarco AlingsPaul DorianHein HeidbuchelJaco HoutgraafPeter KoweyJose MerinoBlandine MondésertJonathan PicciniSean PokorneyPhilip SagerAtul VermaJ Marcus WhartonDavid BharuchaFrancis PlatSilvia ShardonofskyMichael ChenJames IpJames IpAlonzo JonesBruce StamblerDavid SchleinkoferStephen WintersWilson LamRobert GoldsteinIsaac Dor DorSandeep TalwarPadraig O'NeillMichael KorenSean BeinartSrivani AmbatiSean MazerRobert KinnKarine RoyRamin ManshadiRichard KukAditya VermaTimothy PhelanAlexandru StoianKenneth EllenbogenJ Vijay JayachandranTerence ConnellyMarcos DaccarettGaurang GandhiSuneet MittalAmir Abdel-WahabRalph AugostiniJohn IpDenise SorrentinoJean-Francois RouxRamandeep BrarClarence KhooMatthew BennettEric LoBenoit CoutuLaurence SternsGerald GreerPradeep GujjaRobert GianfagnaVijendra SwarupFelix SogadeStephen WiltonChristopher RuisiSaverio BarberaJavier BanchsVictoria KorleyChristopher SchulzeRoger DamleJeffrey Sean Healeya Shekhar PandeyJeffrey AndersonK VenkatachalamPeter NoseworthyBlandine MondésertAtul VermaDouglas FriarsThomas KamburEvan LockwoodGlenn MeiningerGreg OlsovskyAlonzo Jones SrGerald GreerRohit MehtaSaleem AkbarMalik SalmanBhola RamaRamesh AroraDhirenkumar ShahRakesh ShahMichael CammarataAndrew OwensKatherine LudingtonMarcus WhartonMichael BagheriMohammed KhanKenneth Warren CarrSultan SiddiqueSunthosh ParvathaneniSubodh DevabhaktuniAssad MouhaffelGeorge MarkLuigi Di BiaseSunil RangappaJared MortonHirad YarmohammadiAmin KarimAldo Martinez FleitesThomas NeroQaiser ShafiqBenoit CoutuShekhar PandeyYaariv KhaykinJacqueline JozaGilbert GosselinAllen SkanesJohn VyselaarDaniel SavardHein HeidbuchelOlivier XhaetEmmanuel CatezJohan VijgenPascal GodartRuben CasadoGeorges MairesseTom RossenbackerPeter HaemersEtienne HofferPierre HausmanAndras VertesGabor DurayErzsebet SzolnokiZoltan CsanadiFerenc LakatosMarco AlingsReinhart DormanY TuiningaW JansenSebastiaan VelthuisB van BemmelGerhard Jan Willem BechRon PistersSuzanne ValkTjeerd RomerJustin LuermansDriek BeelenMartijn van EckJaco HoutgraafThijs VetDirk ShellingsT OosterhofPawel MiekusWaldemar BebenekAgata Bielecka-DabrowaJacek GniotWitold ZmudaMichal KasprzakWojciech BalakPawel PtaszynskiJacek NowakJanusz ProkopczukAndrzej PrzybylskiIwona Wozniak-SkowerskaPawel DerejkoDanuta CzarneckaAdam JanasJose Luis Merino LlorensLuis TercedorAndres Iniguez RomoRicardo Ruiz GranellJose Ramon Gonzalez JuanateyDomingo Pascual-FigalManuel Martinez-SellesIgnacio Anguera CamosAlicia Ibanez CriadoJavier Matrinez BasterraAlvaro IzquierdoNuria Rivas GandaraJosep Alegret ColomeDiego Perez DiezMiguel Ángel Martínez HervásMaria MedinaJose María Segura Saint-GeronsAlonso Pedrote LealIgnacio Fernandez LozanoAurelio QuesadaJose Guerra RamosAxel SarriasJavier Ramos MaquedaJacques MansouratiPascal DefayeLaurence Guedon-MoreauAntoine MilhemMaxime de GuillebonPhilippe ChevalierMarc BadozCharalampos KriatselisGregor SimonisThorsten LewalterMarkus ZarseAndreas WilkeFabian KraemerAyham Al-Zoebi
-
Organismes :
Hôpital de la Cavale Blanche - CHRU Brest
Optimisation des régulations physiologiques
- Publié dans The Lancet le 02/11/2020
Résumé : Background: Etripamil is a fast-acting, intranasally administered calcium-channel blocker in development for on-demand therapy outside a health-care setting for paroxysmal supraventricular tachycardia. We aimed to evaluate the efficacy and safety of etripamil 70 mg nasal spray using a symptom-prompted, repeat-dose regimen for acute conversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm within 30 min. Methods: RAPID was a multicentre, randomised, placebo-controlled, event-driven trial, conducted at 160 sites in North America and Europe as part 2 of the NODE-301 study. Eligible patients were aged at least 18 years and had a history of paroxysmal supraventricular tachycardia with sustained, symptomatic episodes (≥20 min) as documented by electrocardiogram. Patients were administered two test doses of intranasal etripamil (each 70 mg, 10 min apart) during sinus rhythm; those who tolerated the test doses were randomly assigned (1:1) using an interactive response technology system to receive either etripamil or placebo. Prompted by symptoms of paroxysmal supraventricular tachycardia, patients self-administered a first dose of intranasal 70 mg etripamil or placebo and, if symptoms persisted beyond 10 min, a repeat dose. Continuously recorded electrocardiographic data were adjudicated, by individuals masked to patient assignment, for the primary endpoint of time to conversion of paroxysmal supraventricular tachycardia to sinus rhythm for at least 30 s within 30 min after the first dose, which was measured in all patients who administered blinded study drug for a confirmed atrioventricular-nodal-dependent event. Safety outcomes were assessed in all patients who self-administered blinded study drug for an episode of perceived paroxysmal supraventricular tachycardia. This trial is registered at ClinicalTrials.gov, NCT03464019, and is complete. Findings: Between Oct 13, 2020, and July 20, 2022, among 692 patients randomly assigned, 184 (99 from the etripamil group and 85 from the placebo group) self-administered study drug for atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia, with diagnosis and timing confirmed. Kaplan-Meier estimates of conversion rates by 30 min were 64% (63/99) with etripamil and 31% (26/85) with placebo (hazard ratio 2·62; 95% CI 1·66–4·15; p<0·0001). Median time to conversion was 17·2 min (95% CI 13·4–26·5) with the etripamil regimen versus 53·5 min (38·7–87·3) with placebo. Prespecified sensitivity analyses of the primary assessment were conducted to test robustness, yielding supporting results. Treatment-emergent adverse events occurred in 68 (50%) of 99 patients treated with etripamil and 12 (11%) of 85 patients in the placebo group, most of which were located at the administration site and were mild or moderate, and all of which were transient and resolved without intervention. Adverse events occurring in at least 5% of patients treated with etripamil were nasal discomfort (23%), nasal congestion (13%), and rhinorrhea (9%). No serious etripamil-related adverse events or deaths were reported. Interpretation: Using a symptom-prompted, self-administered, initial and optional-repeat-dosing regimen, intranasal etripamil was well tolerated, safe, and superior to placebo for the rapid conversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm. This approach could empower patients to treat paroxysmal supraventricular tachycardia themselves outside of a health-care setting, and has the potential to reduce the need for additional medical interventions, such as intravenous medications given in an acute-care setting.
Source